S&P 500   4,326.51 (-0.54%)
DOW   34,160.78 (-0.02%)
QQQ   341.10 (-1.01%)
AAPL   159.22 (-0.29%)
MSFT   299.84 (+1.05%)
FB   294.64 (+0.00%)
GOOGL   2,580.10 (-0.18%)
AMZN   2,792.75 (+0.55%)
TSLA   829.10 (-11.55%)
NVDA   219.44 (-3.64%)
BABA   111.79 (-1.39%)
NIO   21.11 (-6.84%)
AMD   102.60 (-7.33%)
CGC   6.85 (-5.26%)
MU   78.72 (-3.96%)
GE   89.90 (+0.65%)
T   24.12 (-0.54%)
F   19.55 (-1.81%)
DIS   135.42 (+1.36%)
AMC   14.52 (-8.91%)
PFE   53.37 (+0.68%)
ACB   3.79 (-6.65%)
BA   189.75 (-2.33%)
S&P 500   4,326.51 (-0.54%)
DOW   34,160.78 (-0.02%)
QQQ   341.10 (-1.01%)
AAPL   159.22 (-0.29%)
MSFT   299.84 (+1.05%)
FB   294.64 (+0.00%)
GOOGL   2,580.10 (-0.18%)
AMZN   2,792.75 (+0.55%)
TSLA   829.10 (-11.55%)
NVDA   219.44 (-3.64%)
BABA   111.79 (-1.39%)
NIO   21.11 (-6.84%)
AMD   102.60 (-7.33%)
CGC   6.85 (-5.26%)
MU   78.72 (-3.96%)
GE   89.90 (+0.65%)
T   24.12 (-0.54%)
F   19.55 (-1.81%)
DIS   135.42 (+1.36%)
AMC   14.52 (-8.91%)
PFE   53.37 (+0.68%)
ACB   3.79 (-6.65%)
BA   189.75 (-2.33%)
S&P 500   4,326.51 (-0.54%)
DOW   34,160.78 (-0.02%)
QQQ   341.10 (-1.01%)
AAPL   159.22 (-0.29%)
MSFT   299.84 (+1.05%)
FB   294.64 (+0.00%)
GOOGL   2,580.10 (-0.18%)
AMZN   2,792.75 (+0.55%)
TSLA   829.10 (-11.55%)
NVDA   219.44 (-3.64%)
BABA   111.79 (-1.39%)
NIO   21.11 (-6.84%)
AMD   102.60 (-7.33%)
CGC   6.85 (-5.26%)
MU   78.72 (-3.96%)
GE   89.90 (+0.65%)
T   24.12 (-0.54%)
F   19.55 (-1.81%)
DIS   135.42 (+1.36%)
AMC   14.52 (-8.91%)
PFE   53.37 (+0.68%)
ACB   3.79 (-6.65%)
BA   189.75 (-2.33%)
S&P 500   4,326.51 (-0.54%)
DOW   34,160.78 (-0.02%)
QQQ   341.10 (-1.01%)
AAPL   159.22 (-0.29%)
MSFT   299.84 (+1.05%)
FB   294.64 (+0.00%)
GOOGL   2,580.10 (-0.18%)
AMZN   2,792.75 (+0.55%)
TSLA   829.10 (-11.55%)
NVDA   219.44 (-3.64%)
BABA   111.79 (-1.39%)
NIO   21.11 (-6.84%)
AMD   102.60 (-7.33%)
CGC   6.85 (-5.26%)
MU   78.72 (-3.96%)
GE   89.90 (+0.65%)
T   24.12 (-0.54%)
F   19.55 (-1.81%)
DIS   135.42 (+1.36%)
AMC   14.52 (-8.91%)
PFE   53.37 (+0.68%)
ACB   3.79 (-6.65%)
BA   189.75 (-2.33%)
NASDAQ:NXTM

NxStage Medical Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
$30.00
0.00 (0.00%)
(As of 02/21/2019)
Add
Compare
Today's Range
$29.98
$30.00
50-Day Range
$30.00
$30.00
52-Week Range
$23.17
$30.00
Volume
2.61 million shs
Average Volume
1.51 million shs
Market Capitalization
$2.00 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.25

Receive NXTM News and Ratings via Email

Sign-up to receive the latest news and ratings for NxStage Medical and its competitors with MarketBeat's FREE daily newsletter.


NxStage Medical logo

About NxStage Medical

NxStage Medical, Inc., a medical technology company, develops, manufactures, and markets products and services for patients suffering from chronic or acute kidney failure. Its primary product includes the System One, a portable hemodialysis system, which is used primarily for home hemodialysis and a range of dialysis therapies to deliver in the home setting. The company operates through three segments: System One, In-Center, and Services. The System One segment sells and rents the NxStage System One and PureFlow SL dialysate preparation equipment, as well as sells disposable products in the home and critical care market for the treatment of end-stage renal disease (ESRD) patients in the home or a home-like setting and in the critical care market for the treatment of hospital-based patients with acute kidney failure or fluid overload. The In-Center segment sells blood tubing sets and needles for hemodialysis primarily for the treatment of ESRD patients at dialysis centers, and needles for apheresis. The Services segment offers dialysis services to patients at NxStage Kidney Care dialysis centers. As of February 3, 2018, it had 21 centers. NxStage Medical, Inc. markets its products through direct sales to dialysis clinics and hospitals in the United States, the United Kingdom, and Canada, as well as through distributors in Europe and internationally. The company was formerly known as QB Medical, Inc. and changed its name to NxStage Medical, Inc. NxStage Medical, Inc. was founded in 1998 and is headquartered in Lawrence, Massachusetts.

Headlines

Omnicell to Buy Ateb, Expand in Adherence Tools Market
October 26, 2021 |  finance.yahoo.com
NxStage Medical (NXTM) - Income Statement
March 27, 2020 |  www.fool.com
FMC wraps up $2 bln acquisition of NxStage
February 22, 2019 |  finance.yahoo.com
NxStage Medical Inc.
February 20, 2019 |  www.barrons.com
U.S. approves Fresenius purchase of NxStage
February 19, 2019 |  feeds.reuters.com
UPDATE 2-U.S. approves Fresenius purchase of NxStage
February 19, 2019 |  feeds.reuters.com
US approves Fresenius purchase of NxStage with conditions
February 19, 2019 |  finance.yahoo.com
Fresenius, NxStage postpone merger date
January 29, 2019 |  www.marketwatch.com
See More Headlines

Industry, Sector and Symbol

Industry
Electromedical equipment
Sub-Industry
Health Care Equipment
Sector
Medical
Current Symbol
NASDAQ:NXTM
CUSIP
67072V10
Fax
N/A
Employees
N/A
Year Founded
N/A

Sales & Book Value

Annual Sales
$393.94 million
Cash Flow
$0.29 per share
Book Value
$3.22 per share

Profitability

Net Income
$-14.47 million
Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
$2.00 billion
Optionable
Optionable

Company Calendar

Last Earnings
8/07/2017
Today
1/27/2022

MarketRank

Overall MarketRank

1.36 out of 5 stars

Medical Sector

1152nd out of 1,419 stocks

Electromedical Equipment Industry

23rd out of 29 stocks

Analyst Opinion: 0.0Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -












NxStage Medical (NASDAQ:NXTM) Frequently Asked Questions

How were NxStage Medical's earnings last quarter?

NxStage Medical, Inc. (NASDAQ:NXTM) posted its earnings results on Monday, August, 7th. The medical device company reported ($0.03) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.03) by $0.00. The medical device company earned $92.20 million during the quarter, compared to analysts' expectations of $96.47 million. NxStage Medical had a negative trailing twelve-month return on equity of 2.50% and a negative net margin of 1.29%. The business's revenue for the quarter was up .0% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.03) earnings per share.
View NxStage Medical's earnings history
.

Who are NxStage Medical's key executives?

NxStage Medical's management team includes the following people:
  • Mr. Jeffrey H. Burbank, Founder, CEO & Director (Age 56)
  • Mr. Joseph E. Turk Jr., Pres (Age 51)
  • Mr. Matthew W. Towse, Sr. VP, CFO & Treasurer (Age 56)
  • Ms. Winifred L. Swan, Sr. VP, Gen. Counsel & Sec. (Age 55)
  • Dr. Allan J. Collins, Head of Scientific Advisory Board & Chief Medical Officer

What other stocks do shareholders of NxStage Medical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NxStage Medical investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Hawkins (HWKN), Chipotle Mexican Grill (CMG), Aegean Marine Petroleum Network (ANW), Athabasca Oil (ATH), Och-Ziff Capital Management Group (OZM), Gran Tierra Energy (GTE) and ALJ Regional (ALJJ).

What is NxStage Medical's stock symbol?

NxStage Medical trades on the NASDAQ under the ticker symbol "NXTM."

What is NxStage Medical's stock price today?

One share of NXTM stock can currently be purchased for approximately $30.00.

How much money does NxStage Medical make?

NxStage Medical has a market capitalization of $2.00 billion and generates $393.94 million in revenue each year. The medical device company earns $-14.47 million in net income (profit) each year or ($0.22) on an earnings per share basis.

What is NxStage Medical's official website?

The official website for NxStage Medical is www.nxstage.com.

Where are NxStage Medical's headquarters?

NxStage Medical is headquartered at 350 MERRIMACK STREET, LAWRENCE MA, 01843.

How can I contact NxStage Medical?

NxStage Medical's mailing address is 350 MERRIMACK STREET, LAWRENCE MA, 01843. The medical device company can be reached via phone at 978-687-4700 or via email at [email protected].


This page was last updated on 1/27/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.